DBV Technologies (NASDAQ:DBVT) Shares Down 9.1% – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price fell 9.1% on Monday . The company traded as low as $17.49 and last traded at $17.3150. 71,626 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 207,616 shares. The stock had previously closed at $19.05.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DBVT shares. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research report on Thursday, December 18th. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Stock Performance

The firm has a market capitalization of $684.93 million, a PE ratio of -3.29 and a beta of -1.17. The business’s 50 day moving average is $16.04 and its two-hundred day moving average is $12.59.

Insiders Place Their Bets

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the sale, the insider directly owned 8,595,472 shares in the company, valued at $41,688,039.20. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.44% of the stock is owned by insiders.

Hedge Funds Weigh In On DBV Technologies

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares in the last quarter. Millennium Management LLC increased its holdings in shares of DBV Technologies by 26.1% in the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after purchasing an additional 69,849 shares during the period. Citadel Advisors LLC purchased a new stake in shares of DBV Technologies in the third quarter worth $220,000. Two Sigma Investments LP purchased a new stake in shares of DBV Technologies in the third quarter worth $167,000. Finally, DLD Asset Management LP bought a new stake in DBV Technologies during the third quarter valued at $250,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.